{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:12:06Z","timestamp":1772741526345,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008331","name":"Universidade Federal Do Rio De Janeiro","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Vancomycin is an antimicrobial agent for treating central nervous system (CNS) infections caused by Gram-positive bacteria. Due to practical and ethical reasons, it is difficult to evaluate vancomycin exposure in cerebrospinal fluid (CSF) and its relationship with therapeutic outcomes. Therefore, alternative methodologies are required. We developed a physiologically based pharmacokinetic (PBPK) model to characterize vancomycin exposure in plasma and CSF in patients with ventriculitis enrolled in a therapeutic drug monitoring program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>PBPK modeling and simulation were conducted using PK-Sim\u00ae version 11.3. A PBPK model was constructed to simulate vancomycin exposure in plasma and CSF. Physicochemical parameters of vancomycin were incorporated into a large molecule model, and tissue distribution was described using the Rodgers-Rowland model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final PBPK model incorporated vancomycin\u2019s low brain permeability by adjusting the CSF-to-plasma partition coefficient to 0.17. Model validation was performed using data from 33 patients with ventriculitis under external ventricular drainage. The dosing regimen consisted of a 30\u00a0mg\/kg loading dose followed by a continuous intravenous infusion of 60\u00a0mg\/kg\/day. Mean simulated vancomycin concentrations in plasma and CSF were 32\u00a0mg\/L and 7.2\u00a0mg\/L, respectively. The predicted CSF\/plasma concentration ratio was 0.22, which closely matched the observed ratio of 0.17.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vancomycin penetration into the CNS is low and variable, highlighting the importance of therapeutic drug monitoring and individualized therapy in patients with ventriculitis. In the future, this model may facilitate the selection of optimal dosing regimens by simulating alternative dosing strategies and establishing PK\/PD relationships for CNS infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-026-04023-5","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T21:42:41Z","timestamp":1770241361000},"page":"345-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Vancomycin Penetration into Cerebrospinal Fluid in Patients with Ventriculitis Using a Physiologically Based Pharmacokinetic Approach"],"prefix":"10.1007","volume":"43","author":[{"given":"Larissa Martins Alves","family":"Guimar\u00e3es","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia Oliveira","family":"de Vasconcellos Nacif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6986-6193","authenticated-orcid":false,"given":"Jhohann Richard","family":"de Lima Benzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0559-1267","authenticated-orcid":false,"given":"Mayra Torres","family":"de Oliveira Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3471-1786","authenticated-orcid":false,"given":"Felipe Francisco","family":"Tuon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4078-2046","authenticated-orcid":false,"given":"Jo\u00e3o Paulo","family":"Telles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-2665","authenticated-orcid":false,"given":"Fernanda","family":"de Lima Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"1","key":"4023_CR1","doi-asserted-by":"publisher","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","volume":"3","author":"NM Brown","year":"2021","unstructured":"Brown NM, Goodman AL, Horner C, Jenkins A, Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist. 2021;3(1):dlaa114. https:\/\/doi.org\/10.1093\/jacamr\/dlaa114.","journal-title":"JAC Antimicrob Resist"},{"issue":"1","key":"4023_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1139\/cjm-2019-0309","volume":"66","author":"E M\u00fchlberg","year":"2020","unstructured":"M\u00fchlberg E, Umst\u00e4tter F, Kleist C, Domhan C, Mier W, Uhl P. Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria. Can J Microbiol. 2020;66(1):11\u20136. https:\/\/doi.org\/10.1139\/cjm-2019-0309.","journal-title":"Can J Microbiol"},{"issue":"11","key":"4023_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036.","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"4023_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10101246","volume":"10","author":"M Ramanan","year":"2021","unstructured":"Ramanan M, Shorr A, Lipman J. Ventriculitis: infection or inflammation. Antibiotics. 2021;10(10): 1246. https:\/\/doi.org\/10.3390\/antibiotics10101246.","journal-title":"Antibiotics"},{"issue":"4","key":"4023_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40262-017-0588-3","volume":"57","author":"N Kumta","year":"2018","unstructured":"Kumta N, Roberts JA, Lipman J, Cotta MO. Antibiotic distribution into cerebrospinal fluid: can dosing safely account for drug and disease factors in the treatment of ventriculostomy-associated infections? Clin Pharmacokinet. 2018;57(4):439\u201354. https:\/\/doi.org\/10.1007\/s40262-017-0588-3.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4023_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/jac\/dky543","volume":"74","author":"U Blassmann","year":"2019","unstructured":"Blassmann U, Hope W, Roehr AC, Frey OR, Vetter-Kerkhoff C, Thon N, et al. CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. J Antimicrob Chemother. 2019;74(4):991\u20136. https:\/\/doi.org\/10.1093\/jac\/dky543.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"4023_CR7","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-017-0548-y","volume":"56","author":"JE Beach","year":"2017","unstructured":"Beach JE, Perrott J, Turgeon RD, Ensom MHH. Penetration of vancomycin into the cerebrospinal fluid: a systematic review. Clin Pharmacokinet. 2017;56(12):1479\u201390. https:\/\/doi.org\/10.1007\/s40262-017-0548-y.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"4023_CR8","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1093\/jac\/dkac332","volume":"77","author":"P Arkell","year":"2022","unstructured":"Arkell P, Wilson R, Watkins K, Antcliffe DB, Gilchrist M, Wilson M, et al. Application of therapeutic drug monitoring to the treatment of bacterial central nervous system infection: a scoping review. J Antimicrob Chemother. 2022;77(12):3408\u201313. https:\/\/doi.org\/10.1093\/jac\/dkac332.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"4023_CR9","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-018-0632-y","volume":"57","author":"N Srinivas","year":"2018","unstructured":"Srinivas N, Maffuid K, Kashuba ADM. Clinical pharmacokinetics and pharmacodynamics of drugs in the central nervous system. Clin Pharmacokinet. 2018;57(9):1059\u201374. https:\/\/doi.org\/10.1007\/s40262-018-0632-y.","journal-title":"Clin Pharmacokinet"},{"key":"4023_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijid.2021.08.001","volume":"110","author":"N Ichinose","year":"2021","unstructured":"Ichinose N, Yoshikawa G, Fukao E, Ichisawa M, Takahata T, Enoki Y, et al. Different intra-cerebrospinal distribution of linezolid in patients with inflammatory meningitis. Int J Infect Dis. 2021;110:382\u20134. https:\/\/doi.org\/10.1016\/j.ijid.2021.08.001.","journal-title":"Int J Infect Dis"},{"key":"4023_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, et al. Applied Concepts in PBPK Modeling: How to Build a PBPK\/PD Model. CPT Pharmacomet Syst Pharmacol. 2016;5:516\u201331. https:\/\/doi.org\/10.1002\/psp4.12134.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"4023_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/FTD.0000000000000907","volume":"43","author":"FF Tuon","year":"2021","unstructured":"Tuon FF, Yamada CH, Cieslinski J, Dos Santos Oliveira D, Ribeiro VST, Gasparetto J, et al. Cerebrospinal fluid penetration of vancomycin during continuous infusion therapy in patients with nosocomial ventriculitis. Ther Drug Monit. 2021;43(6):807\u201311. https:\/\/doi.org\/10.1097\/FTD.0000000000000907.","journal-title":"Ther Drug Monit"},{"key":"4023_CR13","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.namjnl.2025.100018","volume":"1","author":"FS Rezende","year":"2025","unstructured":"Rezende FS, Pinto L, Falc\u00e3o AAO, Paulelli ACC, Mazaro-Costa R, Moraes NV, et al. Next-generation risk assessment: Integrating in vitro data and physiologically-based pharmacokinetic (PBPK) modeling for vancomycin nephrotoxicity evaluation. NAM Journal. 2025;1:100018. https:\/\/doi.org\/10.1016\/j.namjnl.2025.100018.","journal-title":"NAM Journal"},{"key":"4023_CR14","doi-asserted-by":"publisher","unstructured":"OECD, Guidance document on the characterisation, validation and reporting of Physiologically Based Kinetic (PBK) models for regulatory purposes, OECD Series on Testing and Assessment. 2021;331, OECD Publishing, Paris, https:\/\/doi.org\/10.1787\/d0de241f-en.","DOI":"10.1787\/d0de241f-en"},{"issue":"5","key":"4023_CR15","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1128\/AAC.44.5.1356-1358.2000","volume":"44","author":"J Alban\u00e8se","year":"2000","unstructured":"Alban\u00e8se J, L\u00e9one M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother. 2000;44(5):1356\u20138. https:\/\/doi.org\/10.1128\/AAC.44.5.1356-1358.2000.","journal-title":"Antimicrob Agents Chemother"},{"key":"4023_CR16","unstructured":"Open Systems Pharmacology. PK-SIM documentation. https:\/\/docs.open-systems-pharmacology.org\/. Accessed 24 Sept 2025."},{"issue":"4","key":"4023_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","volume":"23","author":"R Nau","year":"2010","unstructured":"Nau R, S\u00f6rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858\u201383. https:\/\/doi.org\/10.1128\/CMR.00007-10.","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"4023_CR18","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","volume":"56","author":"DD Shen","year":"2004","unstructured":"Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev. 2004;56(12):1825\u201357. https:\/\/doi.org\/10.1016\/j.addr.2004.07.011.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"4023_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1086\/510390","volume":"44","author":"JD Ricard","year":"2007","unstructured":"Ricard JD, Wolff M, Lacherade JC, Mourvillier B, Hidri N, Barnaud G, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis. 2007;44(2):250\u20135. https:\/\/doi.org\/10.1086\/510390.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4023_CR20","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1128\/AAC.35.12.2467","volume":"35","author":"PF Viladrich","year":"1991","unstructured":"Viladrich PF, Gudiol F, Li\u00f1ares J, Pallar\u00e9s R, Sabat\u00e9 I, Ruf\u00ed G, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother. 1991;35(12):2467\u201372. https:\/\/doi.org\/10.1128\/AAC.35.12.2467.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4023_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jinf.2014.06.010","volume":"69","author":"S Shokouhi","year":"2014","unstructured":"Shokouhi S, Alavi Darazam I. Determination of vancomycin trough level in serum and cerebrospinal fluid of patients with acute community-acquired meningitis: a prospective study. J Infect. 2014;69(5):424\u20139. https:\/\/doi.org\/10.1016\/j.jinf.2014.06.010.","journal-title":"J Infect"},{"issue":"5","key":"4023_CR22","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3171\/jns.2003.98.5.1040","volume":"98","author":"B Pfausler","year":"2003","unstructured":"Pfausler B, Spiss H, Beer R, Kampl A, Engelhardt K, Schober M, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg. 2003;98(5):1040\u20134. https:\/\/doi.org\/10.3171\/jns.2003.98.5.1040.","journal-title":"J Neurosurg"},{"issue":"6","key":"4023_CR23","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1111\/bcp.14657","volume":"87","author":"KO Jalusic","year":"2021","unstructured":"Jalusic KO, Hempel G, Arnemann PH, Spiekermann C, Kampmeier TG, Ertmer C, et al. Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis. Br J Clin Pharmacol. 2021;87(6):2502\u201310. https:\/\/doi.org\/10.1111\/bcp.14657.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"4023_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10111421","volume":"10","author":"C Tiede","year":"2021","unstructured":"Tiede C, Chiriac U, Dubinski D, Raimann FJ, Frey OR, R\u00f6hr AC, et al. Cerebrospinal fluid concentrations of meropenem and vancomycin in ventriculitis patients obtained by TDM-guided continuous infusion. Antibiotics. 2021;10(11): 1421. https:\/\/doi.org\/10.3390\/antibiotics10111421.","journal-title":"Antibiotics"},{"issue":"3","key":"4023_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/jcph.175","volume":"54","author":"MG Kees","year":"2014","unstructured":"Kees MG, Wicha SG, Seefeld A, Kees F, Kloft C. Unbound fraction of vancomycin in intensive care unit patients. J Clin Pharmacol. 2014;54(3):318\u201323. https:\/\/doi.org\/10.1002\/jcph.175.","journal-title":"J Clin Pharmacol"},{"key":"4023_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.toxlet.2017.05.023","volume":"277","author":"DS Im","year":"2017","unstructured":"Im DS, Shin HJ, Yang KJ, Jung SY, Song HY, Gil HW. Cilastatin attenuates vancomycin-induced nephrotoxicity via P-glycoprotein. Toxicol Lett. 2017;277:9\u201317. https:\/\/doi.org\/10.1016\/j.toxlet.2017.05.023.","journal-title":"Toxicol Lett"},{"issue":"5","key":"4023_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/phar.2388","volume":"40","author":"GM Pais","year":"2020","unstructured":"Pais GM, Liu J, Zepcan S, Avedissian SN, Rhodes NJ, Downes KJ, et al. Vancomycin-induced kidney injury: animal models of toxicodynamics, mechanisms of injury, human translation, and potential strategies for prevention. Pharmacotherapy. 2020;40(5):438\u201354. https:\/\/doi.org\/10.1002\/phar.2388.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"4023_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/psp4.12279","volume":"7","author":"C Emoto","year":"2018","unstructured":"Emoto C, Johnson TN, McPhail BT, Vinks AA, Fukuda T. Using a vancomycin PBPK model in special populations to elucidate case-based clinical PK observations. CPT Pharmacomet Syst Pharmacol. 2018;7(4):237\u201350. https:\/\/doi.org\/10.1002\/psp4.12279.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"12","key":"4023_CR29","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/jcph.6107","volume":"64","author":"W Shuai","year":"2024","unstructured":"Shuai W, Cao J, Qian M, Tang Z. Physiologically based pharmacokinetic modeling of vancomycin in critically ill neonates: assessing the impact of pathophysiological changes. J Clin Pharmacol. 2024;64(12):1552\u201365. https:\/\/doi.org\/10.1002\/jcph.6107.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"4023_CR30","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/jcph.6126","volume":"65","author":"A Cao","year":"2024","unstructured":"Cao A, Li Q, Han M, Liu Q, Liang H, Tan L, Guan Y. Physiologically based pharmacokinetic modeling of vancomycin and its comparison with population pharmacokinetic model in neonates. J Clin Pharmacol. 2024;65(12):1914. https:\/\/doi.org\/10.1002\/jcph.6126.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"4023_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40262-016-0475-3","volume":"56","author":"C Radke","year":"2017","unstructured":"Radke C, Horn D, Lanckohr C, Ellger B, Meyer M, Eissing T, Hempel G. Development of a physiologically based pharmacokinetic modelling approach to predict the pharmacokinetics of vancomycin in critically ill septic patients. Clin Pharmacokinet. 2017;56(7):759\u201379. https:\/\/doi.org\/10.1007\/s40262-016-0475-3.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"4023_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3390\/pharmaceutics17091111","volume":"17","author":"LB Olivo","year":"2025","unstructured":"Olivo LB, de Lemos JLS, Rodrigues VJ, Kretschmer DB, Cruz WdA, Staudt KJ, Annaert P, de Ara\u00fajo BV. PBPK\/PD model of vancomycin in sepsis: linking interstitial exposure in perfusion-limited tissues to MRSA infection. Pharmaceutics. 2025;17(9):1111. https:\/\/doi.org\/10.3390\/pharmaceutics17091111.","journal-title":"Pharmaceutics"},{"issue":"12","key":"4023_CR33","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jiac.2023.08.017","volume":"29","author":"T Maruyama","year":"2023","unstructured":"Maruyama T, Kimura T, Ebihara F, Kasai H, Matsunaga N, Hamada Y. Comparison of the predictive accuracy of the physiologically based pharmacokinetic (PBPK) model and population pharmacokinetic (PPK) model of vancomycin in Japanese patients with MRSA infection. J Infect Chemother. 2023;29(12):1152\u20139. https:\/\/doi.org\/10.1016\/j.jiac.2023.08.017.","journal-title":"J Infect Chemother"},{"issue":"6","key":"4023_CR34","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/cid\/ciw861","volume":"64","author":"AR Tunkel","year":"2017","unstructured":"Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, et al. 2017 Infectious Diseases Society of America\u2019s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis*. Clin Infect Dis. 2017;64(6):e34-65. https:\/\/doi.org\/10.1093\/cid\/ciw861.","journal-title":"Clin Infect Dis"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04023-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04023-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04023-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:38:29Z","timestamp":1772739509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04023-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4023"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04023-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}